Market share reports from healthcare market analytics firms

Eli Lilly's Zepbound Achieves 20.2% Weight Loss, Surpassing Wegovy in Head-to-Head Trial

Dec 4, 2024, 02:10 PM

Eli Lilly announced that its obesity drug Zepbound (tirzepatide) has shown superior results to Novo Nordisk's Wegovy (semaglutide) in the first large, head-to-head trial of the two weight-loss medications. The SURMOUNT-5 Phase 3B trial included 751 adults with obesity or overweight, without type 2 diabetes, each having at least one obesity-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Over 72 weeks, patients taking Zepbound lost an average of 20.2% of their body weight (approximately 50.3 lbs or 22.8 kg), compared to a 13.7% weight loss (approximately 33.1 lbs or 15.0 kg) for those on Wegovy. These results indicate that Zepbound provided a 47% greater relative weight loss compared to Wegovy, highlighting its potential as a more effective treatment for obesity.